Telix Pharmaceuticals Ltd
ASX:TLX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.73
31.14
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
TLX
stock under the Base Case scenario is
13.15
AUD.
Compared to the current market price of 11.89 AUD,
Telix Pharmaceuticals Ltd
is
Undervalued by 10%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Telix Pharmaceuticals Ltd.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Telix’s reliance on complex radiopharmaceutical manufacturing and distribution channels introduces significant logistical and cost risks, potentially limiting timely and efficient market penetration.
Any delays or negative outcomes in late-stage clinical trials for its lead programs—particularly in prostate and kidney cancer diagnostics—could disrupt investor confidence and revenue expectations.
Fierce competition from larger radiopharmaceutical players, coupled with possible constraints in securing sufficient radioisotope supply, may erode Telix’s market share and bargaining power in key geographies.
Telix’s portfolio of targeted radiopharmaceuticals addresses high-unmet-need oncology indications, positioning the firm for rapid market adoption if efficacy and safety data continue to be strong.
Strategic collaborations, including partnerships with global nuclear medicine suppliers, bolster Telix’s capacity to scale up manufacturing and streamline global distribution more efficiently than many emerging biotech competitors.
The firm’s promising theranostic approach—combining diagnostics and therapy—may yield multiple revenue streams, enhancing Telix’s ability to diversify risk and capture a larger share of the nuclear medicine market.
Revenue & Expenses Breakdown
Telix Pharmaceuticals Ltd
Balance Sheet Decomposition
Telix Pharmaceuticals Ltd
| Current Assets | 398m |
| Cash & Short-Term Investments | 207.2m |
| Receivables | 129.5m |
| Other Current Assets | 61.3m |
| Non-Current Assets | 791.9m |
| Long-Term Investments | 36.7m |
| PP&E | 74.2m |
| Intangibles | 584.2m |
| Other Non-Current Assets | 96.9m |
| Current Liabilities | 298.6m |
| Accounts Payable | 51.7m |
| Accrued Liabilities | 54.7m |
| Other Current Liabilities | 192.2m |
| Non-Current Liabilities | 469.4m |
| Long-Term Debt | 397.2m |
| Other Non-Current Liabilities | 72.2m |
Free Cash Flow Analysis
Telix Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Telix Pharmaceuticals Ltd
|
Revenue
|
662.2m
AUD
|
|
Cost of Revenue
|
-305m
AUD
|
|
Gross Profit
|
357.2m
AUD
|
|
Operating Expenses
|
-329.3m
AUD
|
|
Operating Income
|
28m
AUD
|
|
Other Expenses
|
-17.1m
AUD
|
|
Net Income
|
10.8m
AUD
|
TLX Profitability Score
Profitability Due Diligence
Telix Pharmaceuticals Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Telix Pharmaceuticals Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
TLX Solvency Score
Solvency Due Diligence
Telix Pharmaceuticals Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Telix Pharmaceuticals Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLX Price Targets Summary
Telix Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
TLX
is 27.14 AUD
with a low forecast of 17.17 AUD and a high forecast of 36.75 AUD.
Dividends
Current shareholder yield for
TLX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
TLX
stock under the Base Case scenario is
13.15
AUD.
Compared to the current market price of 11.89 AUD,
Telix Pharmaceuticals Ltd
is
Undervalued by 10%.